|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
65,540,000 |
Market
Cap: |
4.24(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$6.84 - $64.7 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 18.1 |
Insider 3/6 Months : 18.7 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Alpine Immune Sciences is a clinical-stage biopharmaceutical company focused on discovering and developing protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Co.'s ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Co.'s ALPN-303 is a dual B cell cytokine antagonist, being developed for the treatment of B cell mediated inflammatory and autoimmune diseases. Co.'s primary oncology program is ALPN-202 (davoceticept) is a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
750,000 |
750,000 |
750,000 |
Total Buy Value |
$0 |
$9,375,000 |
$9,375,000 |
$9,375,000 |
Total People Bought |
0 |
2 |
2 |
2 |
Total Buy Transactions |
0 |
2 |
2 |
2 |
Total Shares Sold |
19 |
3,569,526 |
3,587,529 |
3,587,529 |
Total Sell Value |
$1,227 |
$66,624,154 |
$66,912,708 |
$66,912,708 |
Total People Sold |
1 |
5 |
5 |
5 |
Total Sell Transactions |
1 |
23 |
24 |
24 |
End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Conway Robert |
Director |
|
2017-05-04 |
4 |
B |
$2.26 |
$22,600 |
D/D |
10,000 |
20,000 |
2.39 |
- |
|
Rodman David Malcom |
Exec Vice President and CMO |
|
2017-01-04 |
4 |
AS |
$2.27 |
$15,179 |
D/D |
(6,687) |
11,368 |
|
- |
|
Rodman David Malcom |
Exec Vice President and CMO |
|
2017-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,055 |
18,055 |
|
- |
|
Carruthers R Michael |
Exec Vice President / CFO |
|
2016-12-02 |
4 |
B |
$2.09 |
$50,256 |
D/D |
24,000 |
24,000 |
2.74 |
- |
|
Rodman David Malcom |
Exec Vice President and CMO |
|
2016-10-04 |
4 |
AS |
$7.96 |
$46,327 |
D/D |
(5,820) |
12,236 |
|
- |
|
Rodman David Malcom |
Exec Vice President and CMO |
|
2016-10-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,056 |
18,056 |
|
- |
|
Rodman David Malcom |
Exec Vice President and CMO |
|
2016-07-05 |
4 |
AS |
$4.66 |
$27,727 |
D/D |
(5,950) |
12,105 |
|
- |
|
Rodman David Malcom |
Exec Vice President and CMO |
|
2016-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,055 |
18,055 |
|
- |
|
Congleton Jon |
President and CEO |
|
2016-06-16 |
4 |
B |
$3.87 |
$19,345 |
D/D |
5,000 |
20,000 |
2.81 |
- |
|
Congleton Jon |
President and CEO |
|
2016-03-24 |
4 |
B |
$4.22 |
$21,085 |
D/D |
5,000 |
15,000 |
2.81 |
- |
|
Congleton Jon |
President and CEO |
|
2016-03-22 |
4 |
B |
$4.38 |
$21,908 |
D/D |
5,000 |
10,000 |
2.81 |
- |
|
Congleton Jon |
President and CEO |
|
2015-12-11 |
4 |
B |
$8.10 |
$40,500 |
D/D |
5,000 |
5,000 |
2.81 |
- |
|
Conway Robert |
Director |
|
2015-12-09 |
4 |
B |
$8.10 |
$81,000 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
Deerfield Private Design International Ii, L.p. |
Possible Member of 10% Group |
|
2015-06-23 |
4 |
B |
$14.00 |
$3,500,000 |
I/I |
250,000 |
832,216 |
1.5 |
- |
|
Deerfield Private Design International Ii, L.p. |
Possible Member of 10% Group |
|
2015-06-23 |
4 |
A |
$0.00 |
$0 |
I/I |
3,078,394 |
754,677 |
|
- |
|
Rock Springs Capital Management Lp |
10% Owner |
|
2015-06-22 |
4 |
B |
$14.00 |
$2,800,000 |
I/I |
200,000 |
564,358 |
1.5 |
- |
|
Rock Springs Capital Management Lp |
10% Owner |
|
2015-06-22 |
4 |
A |
$0.00 |
$0 |
I/I |
364,358 |
364,358 |
|
- |
|
Hadley Harbor Master Investors (cayman) L.p. |
10% Owner |
|
2015-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
364,358 |
364,358 |
|
- |
|
Hawkes Bay Master Investors (cayman) L.p. |
10% Owner |
|
2015-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
283,390 |
320,990 |
|
- |
|
Hawkes Bay Master Investors (cayman) L.p. |
10% Owner |
|
2015-06-22 |
4 |
B |
$14.75 |
$81,113 |
D/D |
5,500 |
37,600 |
2.45 |
- |
|
Jennison Global Healthcare Master Fund, Ltd. |
10% Owner |
|
2015-06-22 |
4 |
OE |
$14.00 |
$4,250,834 |
D/D |
303,631 |
329,780 |
|
- |
|
Estate Of Arnold H. Snider, Iii |
10% Owner |
|
2015-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
761,649 |
1,557,228 |
|
- |
|
Hawkes Bay Master Investors (cayman) L.p. |
10% Owner |
|
2015-06-19 |
4 |
B |
$14.67 |
$171,591 |
D/D |
11,700 |
32,100 |
2.45 |
- |
|
Hawkes Bay Master Investors (cayman) L.p. |
10% Owner |
|
2015-06-18 |
4 |
B |
$14.75 |
$91,450 |
D/D |
6,200 |
20,400 |
2.45 |
- |
|
Jennison Global Healthcare Master Fund, Ltd. |
10% Owner |
|
2015-06-17 |
4 |
B |
$14.00 |
$366,086 |
D/D |
26,149 |
26,149 |
2.45 |
- |
|
183 Records found
|
|
Page 7 of 8 |
|
|